mp105
/ Shenzhen Yingsheng Biopharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 31, 2025
Phase Ia Clinical Study Evaluating the Safety and Tolerability of MP105 in Patients with Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, and Esophageal Squamous Cell Carcinoma
(ChiCTR)
- P1 | N=18 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Shenzhen Yingsheng Biopharmaceutical Co., Ltd.
New P1 trial • Colorectal Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma
1 to 1
Of
1
Go to page
1